Novo Integrated Sciences, Inc.: cash and cash equivalents

What this measure means

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Exact concept: us-gaap:CashAndCashEquivalentsAtCarryingValue. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2024-08-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Novo Integrated Sciences, Inc.: total assets
• Novo Integrated Sciences, Inc.: total liabilities
• Novo Integrated Sciences, Inc.: stockholders equity
• Novo Integrated Sciences, Inc.: net income or loss
• Novo Integrated Sciences, Inc.: operating cash flow
• Novo Integrated Sciences, Inc.: capital expenditure payments
• Novo Integrated Sciences, Inc.: contract revenue excluding tax
• Novo Integrated Sciences, Inc.: financing cash flow
• Novo Integrated Sciences, Inc.: investing cash flow
• Novo Integrated Sciences, Inc.: retained earnings or deficit
• Novo Integrated Sciences, Inc.: basic weighted-average shares
• Novo Integrated Sciences, Inc.: diluted weighted-average shares
• Novo Integrated Sciences, Inc.: basic earnings per share
• Novo Integrated Sciences, Inc.: diluted earnings per share
• Novo Integrated Sciences, Inc.: net property, plant and equipment
• Novo Integrated Sciences, Inc.: share-based compensation expense
• Novo Integrated Sciences, Inc.: operating income or loss
• Novo Integrated Sciences, Inc.: current assets
• Novo Integrated Sciences, Inc.: interest expense
• Novo Integrated Sciences, Inc.: current liabilities
• Novo Integrated Sciences, Inc.: current accounts payable
• Novo Integrated Sciences, Inc.: goodwill carrying amount
• Novo Integrated Sciences, Inc.: net finite-lived intangible assets
• Novo Integrated Sciences, Inc.: net current accounts receivable
• Novo Integrated Sciences, Inc.: operating expenses
• Novo Integrated Sciences, Inc.: net inventory
• Novo Integrated Sciences, Inc.: gross profit
• Novo Integrated Sciences, Inc.: cost of revenue
• Novo Integrated Sciences, Inc.: research and development expense
• Novo Integrated Sciences, Inc.: common shares outstanding
• Novo Integrated Sciences, Inc.: additional paid-in capital
• Novo Integrated Sciences, Inc.: accumulated other comprehensive income or loss
• Novo Integrated Sciences, Inc.: total equity including noncontrolling interests
• Novo Integrated Sciences, Inc.: operating lease right-of-use asset
• Novo Integrated Sciences, Inc.: operating lease liability
• Novo Integrated Sciences, Inc.: long-term debt
• Novo Integrated Sciences, Inc.: gross property, plant and equipment
• Novo Integrated Sciences, Inc.: accumulated depreciation on property, plant and equipment
• Novo Integrated Sciences, Inc.: net intangible assets excluding goodwill
• Novo Integrated Sciences, Inc.: accrued current liabilities
• Novo Integrated Sciences, Inc.: prepaid expenses and other current assets
• Novo Integrated Sciences, Inc.: current contract liabilities
• Novo Integrated Sciences, Inc.: net deferred tax liabilities
• Novo Integrated Sciences, Inc.: pre-tax income or loss from continuing operations
• Novo Integrated Sciences, Inc.: profit or loss including noncontrolling interests
• Novo Integrated Sciences, Inc.: comprehensive income or loss
• Novo Integrated Sciences, Inc.: general and administrative expense
• Novo Integrated Sciences, Inc.: depreciation expense
• Novo Integrated Sciences, Inc.: amortization of intangible assets
• Novo Integrated Sciences, Inc.: other nonoperating income or expense
• Novo Integrated Sciences, Inc.: nonoperating income or expense
• Novo Integrated Sciences, Inc.: interest paid, net
• Novo Integrated Sciences, Inc.: proceeds from issuing common stock
• Novo Integrated Sciences, Inc.: operating lease payments
• Novo Integrated Sciences, Inc.: change in accounts receivable
• Novo Integrated Sciences, Inc.: change in inventories
• Novo Integrated Sciences, Inc.: change in accounts payable

Inspect the source

Entity

Novo Integrated Sciences, Inc. / CIK 0001138978

Captured

2026-09-21T17:18:44.141Z

SEC response SHA-256

2c05b67386a7c51ae2db3b1f04bcf71f64bf887526ff32a3b714db1dcc2aff05

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001138978.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))